Serum Insulin-like Growth Factor-1 to Albumin Ratio as a Biomarker for Sarcopenia Severity in End-Stage Renal Disease Patients on Hemodialysis
Sarcopenia is a prevalent and serious complication among patients with End-Stage Renal Disease (ESRD) receiving maintenance dialysis, characterized by progressive loss of skeletal muscle mass, strength, and physical function. It is strongly associated with adverse clinical outcomes, including increased mortality, hospitalization, frailty, and reduced quality of life. The development of sarcopenia in ESRD is multifactorial, involving chronic inflammation, metabolic disturbances, hormonal dysfunction, anorexia, and the catabolic effects of dialysis. Although the 2019 EWGSOP2 guidelines recommend assessment of muscle strength, quantity, and physical performance for diagnosis, routine clinical implementation remains limited due to the need for specialized equipment, time constraints, and variability related to fluid status in dialysis patients. Consequently, there is a growing need for accessible and reliable biochemical markers for early identification of patients at risk.
Insulin-like Growth Factor-1 (IGF-1), an essential anabolic mediator of muscle protein synthesis, is often reduced and functionally impaired in ESRD, contributing to anabolic resistance and muscle wasting. Serum albumin, a conventional indicator of nutritional and inflammatory status, reflects the catabolic and inflammatory processes associated with sarcopenia but lacks specificity when used independently. The IGF-1/Albumin ratio may provide a more integrated representation of the balance between anabolic and catabolic pathways underlying uremic sarcopenia. Therefore, this study aims to evaluate the association between the serum IGF-1/Albumin ratio and the presence and severity of sarcopenia, as defined by EWGSOP2 criteria, in stable outpatient dialysis patients.
研究概览
地位
条件
详细说明
Sarcopenia, defined as a progressive and generalized loss of skeletal muscle mass, strength, and function, represents a formidable comorbidity in patients with End-Stage Renal Disease (ESRD) undergoing maintenance dialysis (Cruz-Jentoft et al., 2019). Its prevalence in this population is alarmingly high, exceeding 50% in some cohorts, and it is independently associated with increased mortality, hospitalization rates, frailty, and diminished quality of life (Kim et al., 2021; Souza et al., 2017). The pathophysiology of sarcopenia in ESRD is multifactorial, driven by a synergistic interplay of chronic inflammation, metabolic acidosis, anorexia, hormonal derangements (including growth hormone resistance), and the catabolic effects of dialysis itself (Lecker et al., 2006).
The diagnosis of sarcopenia, as per the 2019 European Working Group on Sarcopenia in Older People (EWGSOP2) consensus, requires assessment of muscle strength, muscle quantity/quality, and physical performance (Cruz-Jentoft et al., 2019). In clinical nephrology practice, widespread implementation of these criteria is hindered by the need for specialized equipment (e.g., bioimpedance analysis [BIA], dynamometers), time constraints in dialysis units, and variability in test performance due to fluid shifts. Consequently, there is a critical unmet need for a reliable, easily obtainable serum biomarker that can serve as a surrogate or screening tool for identifying and stratifying patients at risk of severe sarcopenia.
Insulin-like Growth Factor-1 (IGF-1) is a pivotal anabolic hormone mediating the effects of growth hormone on muscle protein synthesis. In ESRD, hepatic production of IGF-1 is reduced, and its bioactivity is impaired due to the accumulation of inhibitory binding proteins and uremic toxicity, contributing to the anabolic resistance characteristic of uremic sarcopenia (Huang et al., 2002). Serum albumin is the classical biomarker of nutritional status and a negative acute-phase reactant; low levels reflect both malnutrition and chronic inflammation, two core drivers of muscle wasting (Carrero et al., 2021). However, albumin alone has limited specificity for sarcopenia.
We hypothesize that the IGF-1/Albumin ratio integrates two key pathophysiological axes of uremic sarcopenia: the anabolic deficit (low IGF-1) and the catabolic/inflammatory state (low albumin). This composite ratio may therefore provide a more comprehensive and robust biochemical reflection of the net balance between muscle synthesis and breakdown than either marker alone. While IGF-1 and albumin have been studied independently in CKD, the diagnostic and prognostic utility of their ratio specifically for sarcopenia severity in dialysis patients remains unexplored. This cross-sectional study aims to investigate the association between the serum IGF-1/Albumin ratio and the presence and severity of sarcopenia, as defined by EWGSOP2 criteria, in a stable outpatient dialysis population.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Marian S Ibrahim
- 电话号码:+201018613150
- 邮箱:marian_saeed-post@med.sohag.edu.eg
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
- 1. Adult patients (age ≥ 18 years). 2. Diagnosis of ESRD on maintenance hemodialysis for > 3 months. 3. Clinically stable (no hospitalization or active infection in the past 4 weeks).
4. Willing and able to provide informed consent.
Exclusion Criteria:
1. Active malignancy or recent chemotherapy/radiotherapy. 2. Decompensated liver cirrhosis (Child-Pugh B or C). 3. Major limb amputation or severe neuromuscular disease precluding functional assessment.
4. Acute inflammatory conditions (e.g., systemic lupus erythematosus flare, vasculitis).
5. Pregnancy.
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
|---|
|
Cases
Cases: 110 patients who are ESRD on regular dialyis
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
correlation between the serum IGF-1/Albumin ratio and the severity of sarcopenia
大体时间:6 months
|
To determine the correlation between the serum IGF-1/Albumin ratio and the severity of sarcopenia (categorized as "no sarcopenia," "probable/sarcopenia," and "severe sarcopenia") in prevalent adult patients on maintenance hemodialysis.
|
6 months
|
合作者和调查者
调查人员
- 研究主任:Alo T Ali Hassan, Professor、Sohag University
- 研究主任:Hany A Mohamed Khalil, Lecturer、Sohag University
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- Sohag-Med-26-2-11MS
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.